Successful long-term bilateral subthalamic nucleus deep brain stimulation in VPS35 Parkinson's disease
Vanessa FleuryChristian WiderJudit HorváthAndré ZachariaJulien F. BallyPierre PollakClaudio PolloFrançois VingerhoetsPierre R. Burkhard
9
Citation
5
Reference
10
Related Paper
Citation Trend
Keywords:
LRRK2
Hum
Abstract Genealogical investigation of a large Norwegian family (F04) with autosomal dominant parkinsonism has identified 18 affected family members over four generations. Genetic studies have revealed a novel pathogenic LRRK2 mutation c.4309 A>C (p.Asn1437His) that co‐segregates with disease manifestation (LOD = 3.15, θ = 0). Affected carriers have an early age at onset (48 ± 7.7 SD years) and are clinically asymmetric and levodopa responsive. The variant was absent in 623 Norwegian control subjects. Further screening of patients from the same population identified one additional affected carrier (1 of 692) with familial parkinsonism who shares the same haplotype. The mutation is located within the Roc domain of the protein and enhances GTP‐binding and kinase activity, further implicating these activities as the mechanisms that underlie LRRK2 ‐linked parkinsonism. © 2010 Movement Disorder Society
LRRK2
Norwegian
Cite
Citations (114)
LRRK2
Mendelian inheritance
Cite
Citations (19)
LRRK2
Cite
Citations (0)
Concomitant
Cite
Citations (0)
LRRK2
PINK1
Compound heterozygosity
Cite
Citations (309)
LRRK2
Ethnic chinese
Cite
Citations (152)
Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinson's disease; however, little is known about the expression of LRRK2 in human brain and if/how LRRK2 protein levels are altered in Parkinson's disease.We measured the protein levels of LRRK2 as well as its phosphorylation on serines 910, 935, and 973 in the postmortem brain tissue of Parkinson's disease patients and aged controls with and without Lewy bodies.LRRK2 and its phosphorylation were measured by immunoblot in brain regions differentially affected in Parkinson's disease (n = 30) as well as subjects with Lewy bodies restricted to the periphery and lower brain stem (n = 25) and matched controls without pathology (n = 25).LRRK2 levels were increased in cases with restricted Lewy bodies, with a 30% increase measured in the substantia nigra. In clinical Parkinson's disease, levels of LRRK2 negatively correlated to disease duration and were comparable with controls. LRRK2 phosphorylation, however, particularly at serine 935, was reduced with clinical Parkinson's disease with a 36% reduction measured in the substantia nigra.Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein. © 2016 International Parkinson and Movement Disorder Society.
LRRK2
Lewy body
Cite
Citations (42)
LRRK2
Proband
Cite
Citations (15)
LRRK2
Penetrance
Cite
Citations (82)